The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the ...

Pembrolizumab works by blocking a mechanism that cancer cells use to evade detection by the immune system, according to Drugs ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

Unlocks path towards registrational Phase 3 trial planned to start in 2026Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine ...

Before a wrestling tournament in early 2020, Samuel Gee, then 15, underwent a skin check to make sure he didn’t have ringworm that could spread to others. During the inspection, a referee pointed ...

Unprotected sun exposure and indoor tanning are major contributors to melanoma incidence, highlighting the need for UV protection. Estimates show melanoma diagnoses continuing to climb in the United ...

May is Melanoma Awareness Month and Intermountain Health is unveiling an exciting new treatment program for Utahns with advanced melanoma cancer – the first time local patients have been treated with ...

Various agents are being tried in combination with pembrolizumab for the treatment of advanced melanoma in an attempt to improve the response to pembrolizumab. As noted in this previous Reading Room ...

IFx-2.0, an innate immune agonist, targets resistance to immune checkpoint inhibitors in advanced cutaneous melanoma, receiving FDA orphan drug designation. Phase 1 trials showed IFx-2.0's safety and ...

The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1+, a DNA ...